Stock FNCH FINCH THERAPEUTICS GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Market Closed - Nasdaq
Other stock markets
 21:30:00 26/04/2024 BST 		5-day change 1st Jan Change
2.32 USD +3.57% Intraday chart for Finch Therapeutics Group, Inc. +3.57% -35.73%
03-25 Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-12 Top Premarket Decliners MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Premarket Decliners
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board
Top Premarket Decliners
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions
Finch Therapeutics Group, Inc. Announces Executive Changes
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement
Finch Therapeutics Discontinuing Phase 3 Trial of Proposed Colon Infection Therapy, Slashing 95% of Staff
Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Finch Therapeutics to Reduce Headcount by 37%, Shelves Phase 1 Trial of Autism Drug Candidate; Shares Fall Pre-Bell
Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FNCH Stock
  4. News Finch Therapeutics Group, Inc.
  5. Other languages